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1. Introduction 
Angiogenesis, the formation of new blood vessels from pre-existing, vessels is a crucial 
process for tumor growth and metastasis (Folkman 1990; Kaafarani, Fernandez-Sauze et al. 
2009). The new vessels supply the tumor cells with nutrients and oxygen and ensure 
efficient drainage of metabolites. Under normal conditions, a tissue or tumor cannot grow 
beyond 1 to 2 mm in diameter without neovascularization. This distance is defined by limits 
in the diffusion of oxygen and metabolites, such as glucose and amino acids (Folkman 1971). 
In addition to supplying nutrients for tumor growth, angiogenesis is also a gateway for 
tumor cells and signals to the bloodstream. This direct communication with the bloodstream 
is essential for the dissemination and metastasis of cancer. After their arrival and 
deployment in distant organs, metastatic cells again induce angiogenesis in order to support 
tumor growth (Eichhorn, Kleespies et al. 2007). 
As well as this important role of angiogenesis in tumor growth, the whole process of tissue 
regeneration depends on a new intake of oxygen and metabolites. Growth of new cells for 
regeneration involves a large energy demand that occurs for the process of cellular mitosis. 
Therefore, understanding the biochemical mechanisms involved in angiogenesis is 
necessary for developing interventions in complex tissue regeneration processes. 
Since the hypothesis proposed by the surgeon Judah Folkman in the early 70's, which 
indicated that the inhibition of angiogenesis as a therapeutic target that could halt or even 
reduce tumor growth (Folkman 1971), intense and successful research on the molecular 
mechanisms of angiogenesis tumor began. In recent decades, numerous pro- and anti-
angiogenic molecules, as well as their ligands and intracellular signaling pathways, have 
been identified.  
2. The wound healing process 
The main aim of wound treatment is achieving a rapid closure of the lesion combined with a 
functional and aesthetically satisfactory scar. To improve current practice, it is essential to 
gain a better understanding of the biological processes involved in wound healing and 
tissue regeneration. Many studies have investigated the complex process of wound repair, 
and the cell behaviors, chemical signals and extracellular matrices that together lead to 
scarring. 
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With the disruption of tissue integrity in vertebrates, so begins the repair process, which 
comprises a sequence of molecular events that either restores or at least secures the 
damaged tissue. After birth, the body loses its ability to replace damaged tissue without 
leaving a scar. Only during the fetal stage of life does repair of damage occurs without scar 
formation, with a true restoration of tissue by a neoformation process (Martin and Leibovich 
2005). 
Healing has been conveniently divided into three phases, that overlap temporally: the 
inflammatory, proliferative and remodeling phases (Mendonca and Coutinho-Netto 2009), 
as shown in figure 1. 
2.1 Inflammatory phase (Latent) 
After the occurrence of an injury, tissue begins to leak blood that fills the injured area with 
plasma and cellular elements, mainly platelets. Platelet aggregation and blood clotting 
generate a plug rich in fibrin; this, in addition to restoring hemostasis and form a barrier 
against invading microorganisms, organizes a provisional matrix necessary for cell 
migration. This matrix will also cache growth factors required during the next stages of the 
healing process (Werner and Grose 2003; Eming, Krieg et al. 2007). 
Platelets, essential to the formation of a hemostatic plug, also secrete multiple mediators into 
the injured area. Platelets are essential in the coagulation cascade, and undergo 
degranulation induced by thrombin, releasing growth factors, such as platelet-derived 
growth factor (PDGF), transforming growth factor- (TGF-), epidermal growth factor 
(EGF), transforming growth factor- (TGF-), vascular endothelial growth factor (VEGF) 
and a adhesive glycoproteins such as fibronectin and thrombospondin, which are important 
constituents of the provisional extracellular matrix (Streit, Velasco et al. 2000; Nguyen, 
Hoang et al. 2009; Ribatti 2009). In fact, the coagulation cascade and growth factors released 
by platelets, together with the activation of the complement cascade and activation of 
parenchymal cell by injury, produce numerous vasoactive mediators and chemotactic 
factors, which together assist in the recruitment of inflammatory cells to the wound 
(Delavary, van der Veer et al. 2011). 
In addition to phagocytosing bacteria, cellular debris and foreign bodies, these 
inflammatory cells produce growth factors that prepare the wound for the proliferative 
phase, at which time fibroblasts and endothelial cells will continue to be recruited (Singer 
and Clark 1999; Mendonca and Coutinho-Netto 2009). 
Despite the overlap of the healing phases, there is a basic sequence of events: plasma soluble 
and cellular components exit vessels, followed by platelets, neutrophils and monocytes 
(Delavary, van der Veer et al. 2011). Subsequently, many neutrophils adhere to the 
endothelium and migrate to the region of the wound. However, depletion of neutrophils in 
the blood does not significantly affect the repair process (Simpson and Ross 1972; Werner 
and Grose 2003; Eming, Werner et al. 2007).  
Peripheral blood monocytes, both initially and throughout the course of the healing process, 
continue to infiltrate the wound in response to chemotactic agents for monocytes, such as 
PDGF. In the tissue, monocytes are activated and transform into macrophages, which are 
www.intechopen.com
 
Angiogenesis in Wound Healing 
 
95 
probably the main cells involved in control of the repair process (Singer and Clark 1999; 
Delavary, van der Veer et al. 2011). 
Macrophage activation has implications for various aspects of wound healing, as in the 
phagocytosis of cellular debris, synthesis of extracellular matrix and release of cytokines that 
stimulate increased vascular permeability, angiogenesis and epithelialization. The release of 
factors from platelets is the main stimulus for the migration and macrophage activation, 
while the phagocytosis of cellular components such as fibronectin or collagen also 
contribute (Henderson, Nair et al. 2011). 
The activated macrophage is the main cellular effector in the tissue repair process, 
degrading and removing damaged tissue components such as collagen, elastin and 
proteoglycans. As well as removing cellular debris, macrophages secrete chemotactic factors 
that attract other inflammatory cells to the wound site and produce prostaglandins, which 
act as potent vasodilators and affect the permeability of microvessels (Singer and Clark 1999; 
Eming, Werner et al. 2007). 
Macrophages produce several growth factors such as PDGF, TGF-, fibroblast growth factor 
(FGF) and VEGF, which stand out as the key cytokines necessary to stimulate the formation 
of granulation tissue. Thus, macrophages mediate the initial phase of the inflammatory 
response during the wound healing process (Singer and Clark 1999; Barrientos, Stojadinovic 
et al. 2008). 
 
Fig. 1. Migration of immune cell populations correlated with the phases of wound healing 
2.2 Proliferative phase 
The stage of epithelial proliferation, in the case of the skin, begins with mitogenic and 
chemotactic stimulation of keratinocytes by EGF and TGF-. As important as 
epithelialization, which begins at this stage of the repair process, is the formation of 
granulation tissue, a name given mainly on account of the characteristic granularity 
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resulting from the presence of new capillaries. Granulation tissue is essential to repair 
(Mendonca and Coutinho-Netto 2009). 
Before describing angiogenesis, however, it is necessary to note that increased microvascular 
permeability is the first stage of this process and causes, through the leakage of proteins, 
cytokines and cellular elements, the formation of a provisional extracellular matrix that is 
necessary for migration and proliferation of endothelial cells (Dvorak 2002; Dvorak 2010). 
2.2.1 Vascular permeability 
The production of new blood vessels from pre-existing vessels is accompanied by an 
increase in vascular permeability (Bates and Harper 2002; Dvorak 2010). In pathological 
angiogenesis, increased vascular permeability to water and macromolecules is important to 
the sequence of events that follow injury, being directly responsible for edema. This 
increased capillary permeability seems to have a minor effect during physiological 
angiogenesis but it causes considerable damage in pathologies such as diabetic retinopathy 
(Vaquero, Zurita et al. 2000). 
VEGF-A, for example, was discovered in ascites tumor and was originally noticed for its 
ability to increase the permeability of microvessels and extravasation of macromolecules, 
including fibrinogen and coagulation proteins, to result in extravascular fibrin deposition 
which favors both wound healing and tumor development (Dvorak 2010). 
The mechanisms of vascular permeability regulation, controlled mainly by growth factors, 
have not yet been fully elucidated. The function of these growth factors, and the mechanism 
by which exert their effect, are objects of study of great interest and their metabolic 
pathways are being elucidated (Dvorak 2005). 
2.2.2 Angiogenesis 
Angiogenesis is a fundamental step in the healing process by which new blood vessels are 
formed from preexisting vessels (Folkman and Shing 1992). The new vessels involved in the 
formation of granulation tissue supply the growing tissue with oxygen and nutrients 
(Schafer and Werner 2008).  
In an adult organism, under normal conditions, angiogenesis occurs only in the 
reproductive cycle of females (in utero, with the formation of the endometrium and ovaries, 
with the formation of corpus luteum). Generally, adult vasculature remains quiescent but it 
has the ability to initiate angiogenesis, especially during healing (Schafer and Werner 2008). 
Under physiological conditions, angiogenesis is finely regulated; activated for short periods 
(days) and then completely inhibited. However, many pathologies are a consequence of lack 
of regulation, for example, rheumatoid arthritis, where new blood capillaries invade the 
joint and destroy cartilage. In diabetes, new capillaries present in the retina invade the 
vitreous humor, bleed, and cause blindness. Tumor growth and metastasis are angiogenesis-
dependent diseases, (Folkman 1991). Most tumors remains a constant stimulus to the 
growth of new capillaries to allow their own growth. The blood vessels also provide a route 
of communication that allows tumor cells to invade the bloodstream and cause metastases 
in locations distant from the primary (Folkman and Shing 1992). 
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The induction of angiogenesis was initially attributed to the acidic or basic FGF. 
Subsequently, many other molecules have been identified as angiogenic, including VEGF, 
TGF-, angiogenin, angiotropin and angiopoetin-1 (Folkman and D'Amore 1996). Low 
oxygen tension (Detmar, Brown et al. 1997) and high levels of lactate and bioactive amines 
(Remensnyder and Majno 1968) can also stimulate angiogenesis. Many of these molecules 
are proteins that induce angiogenesis indirectly by stimulating the production of acidic or 
basic FGF and VEGF by macrophages and endothelial cells, direct inducers of angiogenesis. 
2.2.3 Growth factors 
The identification, characterization and purification of VEGF (Vascular Endothelial Growth 
Factor) in 1989 contributed significantly to understanding the regulation of blood flow and 
vascular permeability in angiogenesis (Ferrara and Henzel 1989; Glass, Harper et al. 2006). 
VEGF has three main mechanisms of action: 1) it can increase the vessel permeability to 
water, small solutes and macromolecules (Adamson, Lenz et al. 2004; Nagy, Benjamin et al. 
2008); 2) it can reduce the distance of the tissue cells from to the nearest blood vessel, by 
stimulating angiogenesis, and 3) it can increase blood flow to tissue by acting as potent 
vasodilators (Bates and Harper 2002). 
VEGF exerts its biological activity predominantly through transmembrane receptors with 
tyrosine kinase activity present in endothelial cells and participates as a principal mediator 
of angiogenesis. The VEGF protein family currently includes VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E and placental growth factor (PlGF) (Werner and Grose 2003). VEGF-A is a 
homodimer glycoprotein whose subunits are linked by two disulfide bonds, and is 
synthesized from internal rearrangements ("alternative splicing") of a mRNA, thus there is 
the production of seven isoforms with 121 to 206 amino acids (Ferrara 2001; Bates and 
Harper 2002; Ferrara 2004). Among these, the VEGF121, VEGF165, VEGF189 and VEGF206 
are the predominant isoforms (Kessler, Fehrmann et al. 2007). These isoforms show similar 
biological activities, but differ in their binding properties to heparin and extracellular matrix 
(Roth, Piekarek et al. 2006). The smaller isoforms (121 to 165 amino acids) are secreted in 
soluble form, while larger ones have transmembrane domains, being initially associated 
with cells, where they are released and activated by proteolysis. The VEGF121 is an acid 
protein, while the others have basic isoelectric point. 
VEGF is also known as vascular permeability factor (VPF) due to its potent action in 
increase of vasopermeability, allowing leakage of proteins such as fibrinogen and 
fibronectin, that are essential for the formation of the provisional extracellular matrix (Nagy, 
Benjamin et al. 2008), besides increasing the hydraulic conductivity (Bates and Curry 1997) 
and fenestration (Esser, Wolburg et al. 1998). VEGF also acts as a potent mitogen for 
endothelial cells of the microvasculature inducing endothelial cell migration and sprouting 
of new blood vessels through the regulation of several endothelial integrin receptors (Primo, 
Seano et al. 2010). Furthermore, VEGF also acts as a survival factor for endothelial cells by 
inducing the expression of Bcl-2, an anti-apoptotic protein (Rao, Zhong et al. 2011). 
This family of VEGF exerts its biological functions by differential interactions with three 
transmembrane receptor tyrosine kinase: VEGF receptor-1 (VEGFR-1) [similar to fms 
tyrosine kinase (Flt-1)], VEGFR-2 [fetal liver kinase (Flk-1)] and VEGFR-3 (Flt-4). Expression 
of these receptors is driven primarily by hypoxia. The receptors VEGFR-1 and VEGFR-2 are 
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restricted to the vascular endothelium, while VEGFR-3, together with its preferred ligand, 
VEGF-C and VEGF-D seem to be involved in the growth of lymphatic endothelium 
(Barrientos, Stojadinovic et al. 2008).  
 
Fig. 2. Vascular endothelial growth factor (VEGF) ligands and receptors. VEGF tyrosine 
kinase receptors are subfamily of receptor protein tyrosine kinases (RTKs) and possess an 
extracellular domain containing 7 immunoglobulin-like loops, a single hydrophobic 
membrane-spanning domain, and a large cytoplasmic domain comprising a single catalytic 
domain containing all the conserved motifs found in other RTKs. The extracellular domain 
of VEGFR1 is also independently expressed as a soluble protein (not shown). VEGF-A binds 
with high affinity to both VEGFR2 (KDR/Flk-1) and VEGFR1 (Flt-1) receptors. Placenta 
growth factor (PlGF) and VEGF-B exhibit high-affinity binding to VEGFR1 only. VEGF-C 
and -D are VEGF-related factors that bind to a related receptor, Flt-4 (VEGFR3), and also to 
VEGFR2. Neuropilin-1 (NRP-1) is a novel non-RTK receptor for VEGF165. Neuropilins and 
heparan sulfate proteoglycans act as coreceptors that lack enzymatic activity, yet modulate 
signal output by VEGF receptors. 
VEGF is most likely to act through receptors in the endothelium to increase production of 
nitric oxide (NO) and prostacyclin (PGI2) and augment intracellular endothelial cell survival 
signaling. NO and PGI2 are predicted to have other biological consequences: decreased 
platelet aggregation, thrombosis, and, in the case of NO, inhibition of leukocyte adhesion. 
The combined effect of these biological actions is vascular protection (Zachary 2001). 
Many different cell types, fibroblasts, endothelial cells, macrophages and keratinocytes, 
are able to produce VEGF, and mainly the latter two, are types cells responsible for the 
production during healing (Barrientos, Stojadinovic et al. 2008). The addition of anti-
VEGF inhibits the formation of granulation tissue in the wound (Howdieshell, Callaway 
et al. 2001) indicating an important function of VEGF in angiogenesis that occurs during 
the proliferative phase. Low oxygen tension, as occurs during tissue injury, constitutes the 
greatest inducer of the production of this growth factor (Andrikopoulou, Zhang et al. 
2011). 
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Fig. 3. Mechanisms mediating VEGF-induced NO and PGI2 synthesis. Short-term NO 
production induced by VEGF is mediated via increased cytosolic Ca+2, resulting from 
activation of phospholipase C (PLC-gama) and subsequent generation of inositol  
1,4,5-trisphosphate (IP3). c-Src has been implicated in signaling upstream of PLC-γ. 
Activation of Akt leads to phosphorylation and activation of endothelial NO synthase 
(eNOS-P), providing a mechanism for sustained Ca+2-independent NO synthesis.  
PLC-γ -mediated production of diacylglycerol (DAG) leads to activation of PKC, and this 
pathway plays an important role in mediating VEGF-induced activation of extracellular 
signal-regulated kinases (ERKs). In turn, ERK activation mediates cytosolic phospholipase 
A2 (cPLA2)-mediated PGI2 synthesis. Increased cytosolic Ca+2 also stimulates the cellular 
release of PGI2 (AA, arachidonic acid). 
FGFs are a family of proteins named for their biological activity in promoting the 
proliferation of fibroblasts in culture. Although the FGF family members follow a numerical 
designation (Ornitz and Itoh 2001), the designation FGF has only historical value, since FGFs 
are not only growth factors and their effects are not specifically or universally on fibroblasts. 
The FGF class of proteins comprises 23 members of homologous structure, all being fairly 
small polypeptides with a central core containing 140 amino acids. FGF1 (acidic FGF) and 
FGF2 (basic FGF) are preferentially involved in the process of angiogenesis (Ornitz and Itoh 
2001; Barrientos, Stojadinovic et al. 2008). These compounds are polypeptides of about 18 
kDa, single chained and non-glycosylated. They transmit their signals through FGF 
receptor-4 high-affinity, protein family of transmembrane tyrosine kinases (FGFR-1 to 
FGFR-4), which bind to different FGFs with different affinities. One characteristic of FGF1 
and FGF2 is a strong interaction with glycosaminoglycans such as heparan sulfate, present 
in the extracellular matrix (Folkman, Klagsbrun et al. 1988). This interaction stabilizes FGFs 
against thermal and proteolytic denaturation, also limit its diffusibility. Thus, the 
extracellular matrix acts as a reservoir for pro-angiogenic factors. However, neither the use 
of signal peptide necessary for secretion or release mechanism of these growth factors have 
been determined to date (Werner and Grose 2003). 
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Most members of the FGF family act as a broad spectrum mitogen. They stimulate the 
proliferation of mesenchymal cells of mesodermal origin, as well as ectodermal and 
endodermal cells. In addition to their mitogenic effects, FGFs regulate the migration and 
differentiation of their target cells, also showing the cytoprotective function, which 
increases the survival of cells on adverse conditions (Ornitz and Itoh 2001; Werner and 
Grose 2003).  
The factors FGF1 and FGF2 are synthesized by a variety of cell types involved in 
angiogenesis and wound healing, including inflammatory cells and dermal fibroblasts. They 
act on endothelial cells in a paracrine manner, liberated from the extracellular matrix, or in 
an autocrine way, when released by the endothelial cells themselves, promoting cell 
proliferation and differentiation. During the formation of granulation tissue, FGF2 promotes 
cell migration through surface receptors for integrins, which mediate the binding of 
endothelial cells to extracellular matrix (Barrientos, Stojadinovic et al. 2008). 
In addition, many other growth factors and proteins interact during the orchestrated and 
complex healing process. Proteins such as TGF-beta also act as chemoattractants for 
neutrophils, macrophages and fibroblasts, stimulate the formation of granulation tissue, 
demonstrating its importance throughout the healing process. TGF-beta is an important 
modulator of angiogenesis during wound healing by regulating cell proliferation, migration, 
capillary tube formation and deposition of extracellular matrix (Brunner and Blakytny 2004; 
Verrecchia and Mauviel 2007). 
2.2.4 Extracellular matrix 
For the occurrence of endothelial cell migration and development of new tubular capillaries 
there is a dependence, not only on cells and cytokines present, but also of the production 
and organization of extracellular matrix components including fibronectin, collagen, 
vibronectina, tenascin and laminin, both in the granulation tissue and in the endothelial 
basement membrane. The extracellular matrix is important for normal growth and 
maintenance of vessels because, in addition to acting as a scaffold to cell migration, also acts 
as a reservoir and modulator of the release of growth factors such as FGF2 and TGF- 
(Ruoslahti and Yamaguchi 1991; Brunner and Blakytny 2004). 
Proliferation of endothelial cells, adjacent to and within the wound, leading to the 
deposition of the large amounts of fibronectin in the vessel wall (Pankajakshan and 
Krishnan 2009). Thus, angiogenesis requires the expression of receptors for fibronectin by 
endothelial cells (Brooks, Clark et al. 1994), organizing fibronectin as a conduit to allow their 
movement. Expression and activity of proteases are also necessary for angiogenesis, 
especially during remodeling. 
2.3 Remodeling phase (Repair) 
At this stage of healing, an attempt is made to recover the normal tissue structure. It is a 
period marked by maturation of the elements and by changes in the extracellular matrix, 
resulting in the deposition of collagen and proteoglycans. In a later stage, the fibroblasts of 
the granulation tissue are transformed into myofibroblasts responsive to contractile agonists 
that stimulate smooth muscle. As this occurs, a reorganization of the extracellular matrix 
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takes place, making a final matrix, The balance between the processes that shape this 
determine the balance between regeneration and scarring (Desmouliere, Chaponnier et al. 
2005). 
In the process of maturation and remodeling, most vessels, fibroblasts and inflammatory 
cells disappear from the wound site through migration, apoptosis or other mechanisms of 
cell death. This leads to the formation of scar with a small number of cells. On the other 
hand, if the cells persist at the site, the formation of hypertrophic scars or keloids will occur 
(Mendonca and Coutinho-Netto 2009). 
The main cytokines involved in this phase are tumor necrosis factor (TNF-), interleukin 
(IL-1), PDGF and TGF- produced by fibroblasts, and those produced by epithelial cells 
such as EGF and TGF- (Karukonda, Flynn et al. 2000). 
Re-epithelialization, which covers the wound with new epithelium and involves both 
migration and proliferation of keratinocytes from the periphery of the lesion, also occurs 
during the proliferative phase. These events are regulated by three main agents: growth 
factors, integrins and metalloproteases (Santoro and Gaudino 2005).  
During the inflammatory phase, the release of growth factors in the plasma, fibroblasts and 
macrophages/neutrophils activate keratinocytes located at the margins of the wound. 
Among the growth factors stand out the PDGF that induces the proliferation of fibroblasts 
with consequent production of the extracellular matrix during wound contraction and 
reorganization of the matrix, the keratinocyte growth factor (KGF7) which is considered the 
main regulator of the proliferation of keratinocytes, and TGF-beta, the principal stimulus for 
the initial migration of epithelial cells. The activation of integrins by keratinocytes allows 
cellular interaction with a variety of extracellular matrix proteins in the margin and wound 
bed. On the other hand, the expression and activation of metalloproteinases promotes the 
degradation and modification of extracellular matrix proteins in the wound site, facilitating 
cell migration. The proteolytic activity of these enzymes can release growth factors bound to 
the extracellular matrix in order to maintain a constant stimulus for proliferation and 
migration of keratinocytes, accelerating the process of reepithelialization (Santoro and 
Gaudino 2005). 
There are many diseases that interfere with the tissue repair process; they include diabetes, 
systemic sclerosis, anemia, malnutrition, among others. There are also many conditions that 
make this process difficult to resolve, preventing or delaying a complete tissue restoration. 
By obstructing tissue repair, such diseases or conditions potentially contributing to 
increased morbidity and mortality (Mrué, Coutinho-Netto et al. 2004; Mendonca, Mauricio 
et al. 2010). 
3. Drugs  
In recent decades, several studies have been carried out to identify substances capable of 
promoting the repair process. A search for substances with angiogenic activity has been 
intense, for their great potential for clinical application. 
Among the substances that have direct action in the repair process there are some growth 
factors that, when applied topically to the wound, demonstrat a good ability to accelerate 
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tissue repair in animal experiments (Mustoe, Pierce et al. 1991; Pierce, Tarpley et al. 1994). In 
this group, products based on recombinant human PDGF interfere directly in order to favor 
the repair process, showing good results in healing of ulcers in diabetic patients (Steed 
1998). Other substances containing agents such as enzyme-based ointments DNAse and 
collagenase act to promote wound debridement (Hebda, Klingbeil et al. 1990) and in this 
way assist the course of restoration of tissue. The latter are widely used in clinical practice, 
but have low efficacy in healing chronic wounds. Some angiogenic growth factors and 
inhibitors are listed on table 1 (Ribatti 2009). 
 
Angiogenic growth factors Angiogenesis inhibitors 
Angiogenin Anastellin 
Angiopoietin-1 Angioarrestin 
Del-1 Angiostatin 
Fibroblast growth factors Antiangiogenic antithrombin III 
Granulocyte colony-stimulating  
factor 
CD59 
Hepatocyte growth factor Chondromodulin 
Interleukin-8 Endostatin 
Leptin Heparinases I and III 
Midkine Human chorionic gonadotropin 
Placental growth factor Interferon alfa/beta/gamma 
Plasminogen activator inhibitor-1  
(low concentrations) 
Interferon-inducible protein-10 
Platelet-derived endothelial cell  
growth factor 
Interleukin-12 
Platelet-derived growth factor 2-methoxyestradiol 
Pleiotrophin Placental ribonuclease inhibitor 
Progranulin Plasminogen activator inhibitor-1  
(high concentrations) 
Proliferin Proliferin-related protein 
Transforming growth factor-alfa and beta Retinoids 
Tumor necrosis factor-alfa Tetrahydrocortisol-S 
Vascular endothelial growth factor Thrombospondin-1 
 Tissue inhibitors of matrix 
metalloproteinases 
 Troponin 
 Vasculostatin and Vasostatin 
Table 1. Angiogenic growth factors and inhibitors* 
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Drug name Company Effect on angiogenesis Indications 
Bevacizumab 
(Avastin) 
Genentech Monoclonal antibody 
against VEGF-A. 
Metastatic coloretal 
Ranibizumab 
(Lucentis) 
Genentech Monoclonal antibody that 
binds active forms of 
VEGF-A. 
Age-related macular 
degeneration 
Pegaptanib 
(Macugen) 
Pfizer Selective VEGF inhibitor 
that binds extracellular 
VEGF(165) 
Age-related macular 
degeneration 
Cetuximab (Erbitux) Imclone/ Bristol-Myers 
Squibb 
Human-murine 
monoclonal antibody to 
EGFR 
Metastatic colorectal 
cancer and squamous 
cell carcinoma of the 
head and neck 
Panitumumab 
(Vectibix) 
Amgen Human monoclonal 
antibody to EGFR 
Metastatic colorectal 
cancer 
Trastuzumab 
(Herceptin) 
Genentech Human monoclonal 
antibody to HER-2 
Adjuvant treatment of 
HER-2 overexpressing 
breast cancer and 
metastasis. 
Sunitinib (Sutent) Pfizer Inhibitor of multiples 
RTKs (VEGFRs). 
Advanced renal cell 
and gastrointestinal 
stromal tumors. 
Sorafenib (Nexavar) Bayer/Onyx Inhibitor of multiples 
RTKs (VEGFRs and 
PDGFR). 
Advanced renal cell 
and inoperable 
hepatocellular cancers 
Erlotinib (Tarceva) Genentech/OSI Tyrosine kinase inhibitor 
of EGFR 
Non-small cell lung 
and pancreatic 
cancers 
Batimastat (British) Biotech MMP inhibitor Vascular stents 
Sirolimus/Rapamycin
(Rapamune) 
Wyeth-Ayerst mTOR inhibitor, 
immunosuppressant 
Prophylaxis of organ 
rejection 
Temsirolimus 
(Torisel) 
Wyeth mTOR inhibitor Advanced renal cell 
cancer 
Everolimus  
(Xience V) 
Abbot Afinitor, 
Novartis 
mTOR inhibitor Advanced renal cell 
cancer and vascular 
stents 
Bortezomib  
(Velcade) 
Millenium Proteassome inhibitor, 
down regulation VEGF 
expression
Multiple myeloma 
and mantle cell 
lymphoma 
Imiquimob (Aldara) Graceway 
Pharmaceuticals 
Immune modulator, 
induces production of 
angiogenic inhibitors 
Actinic keratosis, 
superficial BCC and 
external genital warts 
Thalidomide 
(Thalomid) 
Celgene Immune modulator, 
down-regulates 
expression of bFGF and 
VEGF 
Multiple myeloma 
anda erythema 
nodosum leprosum 
EGFR –endothelial growth factor receptor; HER-2 – human estrogen receptor 2; RTK – tyrosine kinase receptor; 
VEGFR – vascular endothelial growth factor receptor; PDGFR – platelet-derived growth factor receptor; MMP – 
matrix metalloproteinase; mTOR – mammalian targed of rapamycin; BCC – basal cell carcinoma. 
Table 2. Antiangiogenics agents approved by FDA (Nguyen, Hoang et al. 2009). 
www.intechopen.com
 
Tissue Regeneration – From Basic Biology to Clinical Application 
 
104 
On the other hand, there is much research on substances that could act to inhibit 
angiogenesis due mainly to their potential for the treatment of cancer. The first angiogenesis 
inhibitors were reported in the 1980s from the Folkman laboratory (interferon-gamma, 
administered at low doses). Subsequently, platelet-factor 4, tetrahydrocortisol, and by 1990, 
a fumagillin analogue were found to have potent antiangiogenic activity.  
Angiostatin, an internal fragment of plasminogen, first revealed that an antiangiogenic 
peptide could be enzymatically released from a parent protein that lacked this inhibitory 
activity. Endostatin, an internal fragment of collagen XVIII, provided the first evidence that 
a basement-membrane collagen contained an angiogenesis inhibitory peptide. Thus new 
drugs with anti-angiogenic activity entered clinical trials. These drugs began to receive 
U.S. Food and Drug Administration (FDA) approval in the United States by 2003. 
Bevacizumab was the first angiogenesis inhibitor approved by the FDA (for colon cancer), 
and the first to demonstrate prolongation of survival in patients with advanced cancer 
(Folkman 2007). It is an anti-VEGF antibody, and the story of its discovery and 
manufacture describes a monumental achievement. However, certain non-endothelial 
cells (haematopoietic-derived cells that colonize tumour stroma and some cancer cells, 
such as those in pancreatic cancer) can also express receptors for vascular endothelial 
growth factor (VEGF; also known as VEGFA), raising the possibility that this drug might 
also have direct anti-tumor effects.  
A new target in therapeutic treatment is the hypoxia-inducible factor 1 (HIF-1) an important 
regulator of cellular response to oxygen deprivation. HIF-1 is a heterodimeric protein that 
consists of alpha (HIF-1 alpha) and beta (HIF-1 beta) subunits. Under regular oxygen 
conditions, HIF-1alpha is continuously expressed but is rapidly destroyed by the 
proteasome pathway. Low oxygen tension results in a decrease in the rate of HIF-1 alpha 
polyubiquination and proteolysis, and consequent accumulation of the protein. Thus, HIF-1-
alpha-HIF-1-beta heterodimers promote angiogenesis, tumor growth, and metastasis 
regulating the expression of many angiogenic factors. Some studies position mTOR as an 
upstream activator of HIF-1 function in cancer cells and suggest that antitumor activity of 
sirolimus (see table 2) is mediated through the inhibition of cellular responses to hypoxic 
stress (Nguyen, Hoang et al. 2009). 
As the treatment range of angiogenesis inhibitors covers not only many types of cancer, 
but also unrelated diseases such as age-related macular degeneration and possibly others, 
angiogenesis inhibitors, or drugs that have varying degrees of antiangiogenic activity, 
might be defined as a class of drugs that specifically target an organizing principle in 
biomedicine.  
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